Provided by Tiger Fintech (Singapore) Pte. Ltd.

Emergent BioSolutions

9.16
-0.2400-2.55%
Post-market: 9.390.2300+2.51%19:55 EDT
Volume:791.68K
Turnover:7.30M
Market Cap:488.70M
PE:3.62
High:9.62
Open:9.30
Low:9.04
Close:9.40
52wk High:12.73
52wk Low:4.02
Shares:53.35M
Float Shares:48.26M
Volume Ratio:0.99
T/O Rate:1.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.53
EPS(LYR):-3.5962
ROE:30.24%
ROA:5.03%
PB:0.91
PE(LYR):-2.55

Loading ...

Emergent BioSolutions EVP Coleen Glessner Reports Disposal of Common Shares

Reuters
·
Oct 17

Aptevo Therapeutics announces interim results for mipletamig in frontline AML from ongoing RAINIER clinical trial

Reuters
·
Oct 08

Emergent BioSolutions Inc to release third quarter 2025 financial results

Reuters
·
Oct 08

Aptevo Therapeutics Files Initial Beneficial Ownership Statement for Bank of America Corp

Reuters
·
Oct 04

Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone

GlobeNewswire
·
Sep 25

Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner

GlobeNewswire
·
Sep 19

Emergent BioSolutions Secures $17 Million Contract for Smallpox Antiviral TEMBEXA® Oral Suspension

Reuters
·
Sep 15

Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension Tembexa® (Brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain

THOMSON REUTERS
·
Sep 15

Emergent BioSolutions Secures $56 Million Contract Modification

TIPRANKS
·
Sep 12

Emergent BioSolutions Secures $56 Million U.S. Government Contract for Smallpox and Mpox Vaccine

Reuters
·
Sep 12

Rayleigh Technology & Precision (001285.SZ), Core Component Manufacturer for Vehicle Active Safety Systems, Plans Initial Public Offering of 45.0445 Million Shares

Stock News
·
Sep 11

Emergent BioSolutions Wins $56 Million Order for Vaccine Supply to US Government

MT Newswires Live
·
Sep 09

BRIEF-Emergent Gets U.S. Contract Update for ACAM2000® Smallpox & Mpox Vaccine

Reuters
·
Sep 09

Emergent BioSolutions Inc - Contract Modification Under Existing 10-Year Aspr Contract

THOMSON REUTERS
·
Sep 09

Emergent BioSolutions Receives New Contract Modification for Acam2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) From the U.S. Government, Further Demonstrating Importance of Public Health Preparedness

THOMSON REUTERS
·
Sep 09

Emergent BioSolutions Secures $30 Million Contract to Supply CYFENDUS® Anthrax Vaccine

Reuters
·
Sep 06

Aptevo Therapeutics Expands Oncology Pipeline with Launch of Trispecific CD3-Directed Anti-Cancer Molecules APVO452 and APVO451

Reuters
·
Sep 04

Emergent Biosolutions Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 03

Emergent BioSolutions Secures $30 Million Contract for Anthrax Vaccine Supply

Reuters
·
Sep 02

Emergent BioSolutions Awarded $30 Million Contract Modification for Cyfendus® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

THOMSON REUTERS
·
Sep 02